

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Presently Amended) A pharmaceutical composition for the treatment of tear and salivary fluid drying, which comprises (-) - (S) -2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4.5]decane or a pharmaceutically acceptable salt thereof as the active ingredient, wherein the pharmaceutical composition is a sustained release composition comprising a sustained release pharmaceutical carrier and wherein the release rate of the active ingredient from the composition is from about 4 percent per hour to about 50 percent per hour.

2. (Original) The pharmaceutical composition for the treatment of tear and salivary fluid drying described in claim 1, wherein the active ingredient is L-tartarate monohydrate of the compound described in claim 1.

3. (Original) The pharmaceutical composition described in claim 1, which has a selective tear and salivary fluid secretion acceleration action.

4. (Original) The pharmaceutical composition described in claim 1 or 3, which has a glandular cell growth action.

5-7. (Canceled)

8. (New) The pharmaceutical composition of claim 1, wherein the active ingredient is released during a period of 2 hours to 24 hours.

9. (New) The pharmaceutical composition of claim 8, wherein the active ingredient is released during a period of 3 hours to 24 hours.

10. (New) The pharmaceutical composition of claim 9, wherein the active ingredient is released during a period of 5 hours to 24 hours.

11. (New) The pharmaceutical composition of claim 1, wherein the sustained release pharmaceutical carrier comprises a hydrophilic base and a hydrogel-forming polymer.

12. (New) The pharmaceutical composition of claim 11, wherein the hydrophilic base is at least one of polyethylene glycol, polyvinyl pyrrolidone, D-sorbitol, and xylitol.

13. (New) The pharmaceutical composition of claim 12, wherein the hydrogel-forming polymer is polyethylene oxide.